Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Noteworthy events during the week of September 29 - October 5 for healthcare investors. More news on: Capricor Therapeutics, Inc., Enanta Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, , Read more ...
WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will hold a conference call and live audio webcast on October 1, 20...
Arvinas (NASDAQ: ARVN ) initiated with Outperform rating and $38 (61% upside) price target at Wedbush. More news on: Arvinas, Inc., Minerva Neurosciences, Inc., Strongbridge Biopharma plc, Healthcare stocks news, Stocks on the move, , Read more ...
WALTHAM, Mass. and SOMERSET, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, and Catalent, the leading global p...
Axsome Therapeutics (NASDAQ: AXSM ) initiated with Outperform rating at William Blair. Shares up 1% premarket. More news on: Axsome Therapeutics, Inc., Canopy Growth Corporation, Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Minerva Neurosciences, Inc. (NERV) Q2 2019 Results Earnings Conference Call August 05, 2019, 08:30 AM ET Company Participants William Boni - Vice President of Investor Relations and Corporate Communications Remy Luthringer - Chief Executive Officer Richard Russell - President G...
Minerva Neurosciences (NASDAQ: NERV ): Q2 GAAP EPS of -$0.32 beats by $0.10 . More news on: Minerva Neurosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive disorder (MDD) and insomnia Patient enrollment progresses in pivotal Phase 3 trial of roluperid...
WALTHAM, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busine...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...